Vitaxin applied molecular evolution

Curr Opin Investig Drugs. 2000 Oct;1(2):199-203.

Abstract

Vitaxin is a humanized version of LM-609 (an mAb licensed from the Scripps Research Institute and Dr David Cheresh in May 1994, which blocks the integrin receptor, alpha v beta 3) [172038]. It is in phase II trials for the potential treatment of leiomyosarcoma [316471] and is also being studied in phase I trials as an anti-inflammatory and potential rheumatoid arthritis therapy [364031,313665]. Vitaxin and non-peptides are under evaluation for use in the treatment of other diseases in which vitronectin is reputed to play a role, e.g., arthritis, psoriasis and other inflammatory diseases. Patent positions are being established on these and other applications, as well as on the structure and use of the non-RGD proteins [182507].

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal / toxicity
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / metabolism
  • Antirheumatic Agents / pharmacology
  • Antirheumatic Agents / therapeutic use*
  • Antirheumatic Agents / toxicity
  • Arthritis, Rheumatoid / drug therapy*
  • Clinical Trials as Topic
  • Contraindications
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / metabolism
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Drugs, Investigational / toxicity
  • Humans
  • Structure-Activity Relationship

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Drugs, Investigational
  • etaracizumab